We support oncology and hematology clinical projects globally – in every phase and virtually every indication, including supportive care.
Clinical Patients
58,400+Clinical Sites
14,900+Clinical Studies
310+Approved Drugs
19Our in-house oncology and hematology experts make the complex, simple. PRA's global project management and clinical operations team members have an average of 10+ years of study experience each.
Team members who possess direct oncology and hematology experience:
of our medical directors
of our directors and managers
of our CRAs
of our clinical team managers
Positioning ourselves as a leader in the immunotherapy space.
The immunotherapy space is advancing rapidly. That’s why we established a cross-functional expert group to keep pace with developments and apply best practices, standards, and expertise to our immuno-oncology trials in multiple treatment modalities, including cellular therapies, oncolytic viruses, cancer vaccines, checkpoint inhibitors, gut microbiome, and other novel approaches. We’ve collated our expertise into a centralized repository of standards and training, and we are streamlining best-in-class onboarding and continual training of our project teams to ensure our capabilities grow with the clinical research landscape.
Cancer Immunotherapy Patients
Cancer Immunotherapy Clinical Sites
Cancer Immunotherapy Studies
Leveraging evidence-based technology to target the right sites for the right patients.
We use evidence-based technology to target the appropriate geographic areas for oncology prevalence and identify a targeted list of investigators with the highest likelihood of accrual. Additionally, we leverage secondary health data such as the natural history of the disease, patient profiling, and key opinion leader identification for decision support in the design and execution of our clinical research studies.
See how strong site selection leads to enrollment success.Executing global studies locally.
Our global investigator network provides access to nearly all geographical areas for patient recruitment, including emergent markets such as Asia, Latin America, and Eastern Europe. However, it is our team’s practical knowledge of local regulations, standards of care, and cultural customs that enables us to maximize safety and efficiency in our oncology and hematology studies.
We’re proactively establishing preferred access to investigative sites able to deliver high-quality clinical data so that we can conduct accurate feasibility studies and more effectively recruit patients. This approach results in fast study start-ups and potentially reduced overall development timelines for our sponsors.
You may also be interested in:
Capability
ECG Assessments During the Development of Oncology Compounds
Single-center oncology studies performed by dedicated PRA staff, combined with the High Precision QT approach of iCardiac, generates conclusive ECG…
Case Study
PRA Successfully Rescues Phase II Hematology Study
A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to…
Case Study
Meeting Enrollment Goals Breast Cancer
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in…